Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES (GILD)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Gilead Sciences' : Trademark Application for "LEAP EDUCATION AND ACCESS PROGRAM" Filed

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 11:57pm CET

By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a trademark application has been made for "LEAP EDUCATION AND ACCESS PROGRAM" by Gretchen R. Stroud, representing Gilead Sciences. This application was made available to the public on September 25, 2017 (see also Pharmaceutical Companies).

The serial number for this application is 85086605.

The international trademark goods and services class codes for this trademark application are 035 and 044. The applicant indicates that "Color is not claimed as a feature of the mark. The mark consists of a swirl design above the words 'LEAP EDUCATION AND ACCESS PROGRAM'."

As submitted by the applicant, this trademark application relates to the following goods and services:

• Assisting patients in enrolling in pharmaceutical reimbursement programs;

• Providing health information, namely, providing information about the treatment of pulmonary arterial hypertension.

The owner/registrar information for this application is: Gretchen R. Stroud, Gilead Sciences, 333 Lakeside Dr, Foster City, CA 94404-1147.

Keywords for this news article include: Pharmaceutical Companies, Trademarks, Gilead Sciences.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
12/15 GILEAD SCIENCES : Galapagos exercises co-promotion option for filgotinib with co..
12/14 GILEAD SCIENCES : Announces That John C. Martin, PhD Will Transition From Execut..
12/14 GILEAD SCIENCES : Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yes..
12/14 GILEAD SCIENCES : Kite Announces Data from ZUMA-3 Study of KTE-C19 in Adult Pati..
12/14 GILEAD SCIENCES : ex-dividend day
12/13 Celgene, Gilead, and Regeneron are On the Mend
12/13 GILEAD SCIENCES : Kite Announces Data From ZUMA-3 Study of KTE-C19 in Adult Pati..
12/13 GILEAD SCIENCES : (GILD) Posts Updated Data on CAR-T Therapy Yescarta
12/12 GILEAD SCIENCES : adds to CAR-T assets with Cell Design Labs buyout
12/12 GILEAD SCIENCES : Kite Announces Data From ZUMA-3 Study of KTE-C19 in Adult Pati..
More news
News from SeekingAlpha
03:00a Gilead Sciences - The Silver Bullet For NASH With Selonsertib And GS-9674 Com..
12/16 Venture capital deals of the week
12/15 MY JOURNEY TO FINANCIAL INDEPENDENCE : 86-Stock November Portfolio Update - Buyi..
12/15 UPCOMING CONVERSATION WITH AN EXPERT : Highlights In CAR-T
12/15 Teva launches generic Viread in U.S.
Financials ($)
Sales 2017 25 816 M
EBIT 2017 15 661 M
Net income 2017 10 511 M
Debt 2017 12 742 M
Yield 2017 2,80%
P/E ratio 2017 9,71
P/E ratio 2018 12,66
EV / Sales 2017 4,32x
EV / Sales 2018 4,89x
Capitalization 98 689 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 85,7 $
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES6.94%98 689
REGENERON PHARMACEUTICALS5.33%41 789
VERTEX PHARMACEUTICALS96.55%36 888
GENMAB-11.85%9 967
BLUEBIRD BIO INC199.68%8 385
EXELIXIS, INC.78.27%7 722